ABSTRACT

In this issue of
The human genome is predicted to code for ~1000 molecularly distinct G protein-coupled receptors (GPCRs) (Takeda et al., 2002; Fredriksson et al., 2003) . GPCRs therefore represent one of the largest protein families found in nature. An extraordinarily large number of drugs in current clinical use exert their therapeutic effects via binding to specific GPCR subtypes, underscoring the great clinical importance of this class of receptors. The vast majority of these drugs stimulate or inhibit receptor activity by interacting with the binding site recognized by the endogenous ligand, the so-called 'orthosteric' binding site. Consequently, most clinically used GPCR ligands represent either orthosteric agonists (agents that mimic the action of the endogenous GPCR ligands), neutral antagonists, or inverse agonists. However, a considerable body of work suggests that GPCRs, like many other signaling molecules or enzymes, are endowed with one or more additional, so-called 'allosteric', sites that are recognized by allosteric ligands or modulators (Christopoulos 2002; Christopoulos and Kenakin, 2002; Birdsall and Lazareno, 2005; Gao and Jacobson, 2005) . By definition, these allosteric binding sites are distinct from the sites involved in the binding of orthosteric ligands, allowing allosteric and orthosteric agents to bind to their target receptors simultaneously (Christopoulos 2002; Christopoulos and Kenakin, 2002; Birdsall and Lazareno, 2005) . A variety of different radioligand binding and functional approaches have been used to characterize the binding and functional properties of allosteric GPCR ligands (for recent reviews, see Christopoulos 2002; Christopoulos and Kenakin, 2002; Mohr et al., 2003; Birdsall and Lazareno, 2005; Ehlert, 2005 Christopoulos and Kenakin, 2002; Birdsall and Lazareno, 2005) .
Various members of each of the three major GPCR subfamilies (A, B, and C) have been shown to be subject to allosteric modulation by small molecule ligands (Christopoulos 2002; Christopoulos and Kenakin, 2002; Presland, 2005; Gao and Jacobson, 2005) . During the past three decades, the muscarinic acetylcholine (ACh) receptors (mAChRs) have served as an excellent model system to study the molecular mechanisms by which GPCR activity can be modulated by allosteric drugs (Ellis, 1997; Christopoulos, 2002; Mohr et al., 2003; Birdsall and Lazareno, 2005) . The five mAChRs (M 1 -M 5 ), like most other GPCRs, are prototypic class A (rhodopsin-like) GPCRs (Wess, 1996; Caulfield and Birdsall, 1998; Hulme et al., 2003) . All five mAChR subtypes have been shown to be subject to allosteric modulation. However, the molecular nature of this modulation differs among the individual receptor subtypes and depends on the choice of This article has not been copyedited and formatted. The final version may differ from this version. (Ellis, 1997; Christopoulos, 2002; Mohr et al., 2003; Birdsall and Lazareno, 2005) .
The amino acids forming the binding site for orthosteric muscarinic ligands are located within the exofacial portions of various transmembrane (TM) helices, primarily TM domains III, V, VI, and VII (Wess, 1996; Hulme et al., 2003) . The receptor binding site for allosteric muscarinic ligands is thought to be located close to the orthosteric site but at a more extracellular level, involving residues located in the extracellular loops and the outermost segments of different TM helices (Matsui et al., 1995; Ellis, 1997; Christopoulos, 2002; Mohr et al., 2003; Birdsall and Lazareno, 2005) .
Drugs that can stimulate or inhibit the activity of individual mAChR subtypes with high selectivity may become therapeutically useful in the treatment of many pathophysiological conditions including Alzheimer's and Parkinson's disease, schizophrenia, and drug abuse (Felder et al., 2000; Wess, 2004; Eglen, 2005) . However, the amino acids involved in ACh binding are highly conserved among the M 1 -M 5 mAChRs (Wess, 1996; Caulfield and Birdsall, 1998; Hulme et al., 2003) , most likely due to evolutionary pressures. For this reason, orthosteric muscarinic ligands that can interact with distinct mAChR subtypes with a very high degree of selectivity are not available at present. On the other hand, the extracellular surface of the M 1 -M 5 mAChRs, including the three extracellular loops, is less well conserved than the TM receptor core containing the binding site for orthosteric ligands (Wess, 1996; Ellis, 1997; Caulfield and Birdsall, 1998) .
Since the allosteric muscarinic binding site is predicted to involve receptor epitopes located extracellular of the ACh binding site, it is likely that these sequence differences can be exploited to develop receptor subtype-selective allosteric muscarinic ligands. Interestingly, accumulating evidence suggests that mAChRs may be endowed with at least two allosteric binding sites (Christopoulos, 2002; Mohr et al., 2003; Birdsall and Lazareno, 2005) . One key observation supporting this concept is that certain allosteric muscarinic ligands such as gallamine or strychnine. Moreover, several allosteric muscarinic ligands, including the acetylcholinesterase inhibitor tacrine (Potter et al., 1989) and the bis-pyridinium derivative Duo3 (Tränkle and Mohr, 1997; Schröter et al., 2000) , have been identified which, in contrast to conventional allosteric muscarinic ligands, display concentration-effect curves with slope factors >1. The complex binding properties of Duo3 suggested that this ligand, similar to the above-mentioned indolocarbazole and androstane derivatives, may interact with a second allosteric binding site (Tränkle and Mohr, 1997; Schröter et al., 2000; Tränkle et al., 2003) . In this issue, Tränkle et al. present new findings regarding the existence of a second allosteric site on the M 2 mAChR and provide data suggesting that two molecules of an allosteric agent and one orthosteric ligand may be able to bind to the M 2 mAChR simultaneously (Fig. 1) The binding of muscarinic ligands to these allosteric sub-domains is predicted to be governed by different structure-function relationships Birdsall and Lazareno, 2005) . This observation should guide medicinal chemists in designing novel allosteric drugs acting at distinct mAChR or other GPCR subtypes. Interestingly, the FDA has recently approved the first allosteric GPCR ligand, cinacalcet (an allosteric enhancer acting on the calcium-sensing receptor), for the treatment of certain forms of secondary hyperparathyroidism and hypercalcemia (Block et al., 2004; Lindberg et al., 2005) .
Primarily due to the experimental designs used, past drug discovery efforts have yielded a large number of clinically important drugs acting on the orthosteric site of GPCRs. It is likely that the application of new methodologies including high-throughput functional screening techniques will lead to the identification of many novel allosteric GPCR ligands (Christopoulos 2002; Presland, 2005) . Such agents are of considerable therapeutic potential since their use is predicted to be associated with increased efficacy and reduced side effects, as compared to classic orthosteric ligands (Table 1) .
This article has not been copyedited and formatted. The final version may differ from this version. ligands are thought to be located within the extracellular loops and the outermost segments of different TM helices (Matsui et al., 1995; Ellis, 1997; Christopoulos, 2002; Mohr et al., 2003; Birdsall and Lazareno, 2005) . In this model, two molecules of tacrine (yellow and green structures) are bound simultaneously within the allosteric binding cleft. Use of colors and abbreviations: TM helices (I-VII), red; N-terminal domain (N) and first (o1) and third (o3) extracellular loops, grey; second extracellular loop (o2), cyan; cysteine residues involved in disulfide bond formation, magenta.
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